Molecular Insight Pharmaceuticals, Inc. To Announce First Quarter Financial Results on May 14, 2008
Cambridge, MA, May 5, 2008 – Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced today that it will release its first quarter 2008 financial results before the opening of the stock market and hold a conference call on Wednesday, May 14, 2008 at 10:00 AM Eastern Time. During the call, senior management of Molecular Insight will review the company’s financial results and provide an update on its clinical development programs.
Conference Call Details
To access the live call on May 14, 2008 at 10:00 AM Eastern Time, dial (888) 713-4213 or (617) 213-4865 (for international participants) at least five minutes prior to the start of the call. The participant pass code is 57768065. For one week following the call, an audio replay can be accessed by dialing (888) 286-8010 or (617) 801-6888 (for international participants) and using the pass code 21132976.
Participants may pre-register for the call to expedite access and minimize hold times by visiting https://www.theconferencingservice.com/prereg/key.process?key=PK7C38N87.
A live audio webcast of the call will also be available in the "Investor Relations" section of the company's website, www.molecularinsight.com. After the event, an archived audio webcast will be available on the company’s website for 30 days.
About Molecular Insight Pharmaceuticals, Inc.
Molecular Insight Pharmaceuticals (NASDAQ: MIPI) is a biopharmaceutical company specializing in the emerging field of molecular medicine, applying innovations in the identification and targeting of disease at the molecular level to improve healthcare for patients with life-threatening diseases. The company is focused on discovering, developing and commercializing innovative, molecular radiotherapeutics and molecular imaging pharmaceuticals with initial applications in the areas of oncology and cardiology. Its lead molecular radiotherapeutic product candidates, Azedra and Onalta, are being developed for detection and treatment of cancer. The company's lead molecular imaging pharmaceutical product candidate, Zemiva, is being developed for the diagnosis of cardiac ischemia, or insufficient blood flow to the heart. In addition, the company has a growing pipeline of product candidates resulting from application of its proprietary platform technologies to new and existing compounds. Molecular Insight Pharmaceuticals is based in Cambridge, Massachusetts and its website address is: www.molecularinsight.com.
Forward-Looking Statements
Statements in this release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, statements about the development of AzedraTM, OnaltaTM, ZemivaTM and our other product candidates. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results of Molecular Insight to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for product candidates; competition from other pharmaceutical or biotechnology companies; and the additional risks discussed in filings with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement, and Molecular Insight undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.
Contact:
Priscilla Harlan
Vice President, Corporate Communications
Molecular Insight Pharmaceuticals, Inc.
(617) 492-5554